Evidence Map v1

See the shape of every peptide record

Compare selected trials, PubMed bibliography, regulatory records, source-year reach, structured detail, and known collection gaps across all 116 canonical profiles.

Choose your view

Compare two or three peptides

Inspect selected evidence side by side. These collections cover different studies, populations, and dates; they cannot establish which treatment is better. Registry phases describe study records, not results.

Showing Semaglutide and Tirzepatide. Column order is not a ranking.

On a narrow screen, scroll the table horizontally to see every selected profile.

Selected evidence, coverage gaps, and source dates
Evidence dimensionSemaglutideTirzepatide
Reviewed human evidence

A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.↗↗

Read the reviewed studies and limitations →

A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.↗↗

Read the reviewed studies and limitations →

Trial phases at observation
  • Phase 3: 22 selected records
  • Phase 2: 19 selected records
  • Phase 1: 12 selected records
  • Phase 4: 10 selected records
  • Not applicable: 4 selected records

76 of 140 selected trial records lack structured phase detail. A record can list more than one phase.

Inspect the cited trial observations →
  • Phase 2: 22 selected records
  • Phase 3: 13 selected records
  • Phase 4: 13 selected records
  • Phase 1: 7 selected records
  • Early Phase 1: 2 selected records
  • Not applicable: 2 selected records

54 of 108 selected trial records lack structured phase detail. A record can list more than one phase.

Inspect the cited trial observations →
Regulatory records

FDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗

  • 5 connected Drugs@FDA applications
  • 13 Federal Register documents
  • 19 DailyMed label versions

Record counts do not establish approval for an ingredient, use, or formulation.

Inspect regulatory connections →

FDA-approved as Mounjaro and Zepbound↗↗↗

  • 2 connected Drugs@FDA applications
  • 8 Federal Register documents
  • 22 DailyMed label versions

Record counts do not establish approval for an ingredient, use, or formulation.

Inspect regulatory connections →
Coverage gaps

All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence.

  • How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?↗↗
Inspect coverage and missing fields →

All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence.

  • What are the durability, post-discontinuation outcomes, and uncommon harms across broader populations and longer follow-up?↗↗
Inspect coverage and missing fields →
Review and check dates

Status sources checked through: July 22, 2026. Status evidence →

Human evidence reviewed through: August 18, 2026.

Review source snapshots checked: August 18, 2026.

Integrity checked: August 19, 2026.

Review dates and source snapshots →

These dates do not imply continuous monitoring.

Status sources checked through: August 14, 2026. Status evidence →

Human evidence reviewed through: August 19, 2026.

Review source snapshots checked: August 19, 2026.

Integrity checked: August 19, 2026.

Review dates and source snapshots →

These dates do not imply continuous monitoring.

Share this page’s URL to preserve your selection. Each evidence cell links to the cited source or its detailed evidence view.

Canonical profiles

116 deterministic maps

Open the research atlas →

No dated records selected source window

5-Amino-1MQ

0 dated records0/4 lanes present0 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Literature metadata, Regulatory, Safety.

Open the full map →

2017–2026 selected source window

Abaloparatide

60 dated records3/4 lanes present10 source years
  • Trials 9 2 with phase · 2 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 33 9 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 11 dated AP submissions · 23 official documents
  • DailyMed 16 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2009–2026 selected source window

Afamelanotide

55 dated records3/4 lanes present12 source years
  • Trials 16 2 with phase · 2 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 25 5 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 2 dated AP submissions · 5 official documents
  • DailyMed 11 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2014–2021 selected source window

Albiglutide

19 dated records3/4 lanes present8 source years
  • Trials 13 13 with phase · 13 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 4 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Amycretin

9 dated records2/4 lanes present2 source years
  • Trials 6 6 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 3 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2007–2016 selected source window

AOD-9604

2 dated records1/4 lanes present2 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 2 2 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2024–2026 selected source window

Apraglutide

8 dated records1/4 lanes present3 source years
  • Trials 8 8 with phase · 8 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2022–2026 selected source window

Avexitide

3 dated records1/4 lanes present3 source years
  • Trials 3 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2019–2026 selected source window

Aviptadil

9 dated records2/4 lanes present5 source years
  • Trials 2 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 7 7 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

1998–2026 selected source window

Bivalirudin

78 dated records3/4 lanes present19 source years
  • Trials 30 28 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 14 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

BPC-157

53 dated records3/4 lanes present7 source years
  • Trials 2 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 49 24 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2011–2026 selected source window

Bremelanotide

32 dated records3/4 lanes present13 source years
  • Trials 6 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 21 5 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 2 dated AP submissions · 5 official documents
  • DailyMed 2 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2022–2026 selected source window

Cagrilintide

14 dated records2/4 lanes present4 source years
  • Trials 8 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 6 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

1978–2026 selected source window

Calcitonin salmon

57 dated records3/4 lanes present20 source years
  • Trials 4 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 15 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2012–2026 selected source window

Carfilzomib

62 dated records3/4 lanes present10 source years
  • Trials 29 29 with phase · 29 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 6 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2010–2026 selected source window

Cerebrolysin

47 dated records2/4 lanes present12 source years
  • Trials 21 19 with phase · 21 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 26 26 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2000–2026 selected source window

Cetrorelix

56 dated records3/4 lanes present18 source years
  • Trials 26 25 with phase · 26 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 22 22 with bibliography
  • Drugs@FDA 7 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2020 selected source window

Cibinetide

4 dated records2/4 lanes present3 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 3 3 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2010–2026 selected source window

CJC-1295

10 dated records2/4 lanes present8 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 9 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2020–2025 selected source window

Cotadutide

3 dated records1/4 lanes present3 source years
  • Trials 3 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2009–2026 selected source window

Dalbavancin

46 dated records3/4 lanes present12 source years
  • Trials 11 10 with phase · 11 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 6 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2003–2026 selected source window

Daptomycin

102 dated records3/4 lanes present17 source years
  • Trials 30 30 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 32 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

Dasiglucagon

20 dated records3/4 lanes present8 source years
  • Trials 16 16 with phase · 16 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 2 2 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2008–2026 selected source window

Degarelix

63 dated records3/4 lanes present18 source years
  • Trials 30 29 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 31 31 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1978–2026 selected source window

Desmopressin

101 dated records3/4 lanes present29 source years
  • Trials 25 24 with phase · 25 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 38 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2020–2026 selected source window

Difelikefalin

24 dated records3/4 lanes present7 source years
  • Trials 6 6 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 14 14 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2021 selected source window

Dihexa

1 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2014–2026 selected source window

Dulaglutide

92 dated records4/4 lanes present13 source years
  • Trials 11 5 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 38 14 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 22 dated AP submissions · 42 official documents
  • DailyMed 39 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2019–2026 selected source window

Efinopegdutide

10 dated records2/4 lanes present4 source years
  • Trials 9 9 with phase · 9 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2014–2026 selected source window

Efpeglenatide

7 dated records2/4 lanes present4 source years
  • Trials 6 6 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2013–2026 selected source window

Elamipretide

51 dated records3/4 lanes present8 source years
  • Trials 10 5 with phase · 5 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 39 15 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Eloralintide

20 dated records2/4 lanes present2 source years
  • Trials 19 19 with phase · 19 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2003–2026 selected source window

Emideltide

44 dated records2/4 lanes present13 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 42 17 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2003–2026 selected source window

Enfuvirtide

49 dated records3/4 lanes present16 source years
  • Trials 22 22 with phase · 22 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2012–2026 selected source window

Epitalon

26 dated records2/4 lanes present6 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 24 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

1997–2026 selected source window

Eptifibatide

65 dated records3/4 lanes present19 source years
  • Trials 16 16 with phase · 16 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 15 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

Etelcalcetide

47 dated records3/4 lanes present9 source years
  • Trials 17 17 with phase · 17 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 28 28 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2005–2026 selected source window

Exenatide

120 dated records3/4 lanes present20 source years
  • Trials 50 3 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 49 25 with bibliography
  • Drugs@FDA 5 exact reviewed application connections
  • FDA history 87 dated AP submissions · 152 official documents
  • DailyMed 5 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

No dated records selected source window

Follistatin-344

0 dated records0/4 lanes present0 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Literature metadata, Regulatory, Safety.

Open the full map →

2022–2025 selected source window

FOXO4-DRI

2 dated records1/4 lanes present2 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 2 2 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2016–2026 selected source window

Gallium Ga 68 dotatate

13 dated records3/4 lanes present6 source years
  • Trials 6 5 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 6 6 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1999–2026 selected source window

Ganirelix

42 dated records3/4 lanes present17 source years
  • Trials 27 22 with phase · 27 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 6 6 with bibliography
  • Drugs@FDA 8 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2015–2026 selected source window

GHK-Cu

17 dated records1/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 17 5 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2008–2025 selected source window

GHRP-2

21 dated records1/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 21 21 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2016–2026 selected source window

GHRP-6

25 dated records1/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

1996–2026 selected source window

Glatiramer acetate

65 dated records3/4 lanes present16 source years
  • Trials 26 24 with phase · 26 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 11 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

Glepaglutide

9 dated records2/4 lanes present6 source years
  • Trials 8 8 with phase · 8 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

1960–2026 selected source window

Glucagon

315 dated records4/4 lanes present23 source years
  • Trials 31 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 255 136 with bibliography
  • Drugs@FDA 10 exact reviewed application connections
  • FDA history 92 dated AP submissions · 72 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

1982–2026 selected source window

Gonadorelin

22 dated records3/4 lanes present13 source years
  • Trials 5 5 with phase · 5 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 16 16 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1989–2026 selected source window

Goserelin

64 dated records3/4 lanes present17 source years
  • Trials 30 30 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2012–2026 selected source window

Hexarelin

24 dated records1/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 24 24 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

1991–2026 selected source window

Histrelin

10 dated records3/4 lanes present9 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 5 5 with bibliography
  • Drugs@FDA 3 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2011–2026 selected source window

Humanin

25 dated records1/4 lanes present8 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2007–2026 selected source window

Icatibant

64 dated records3/4 lanes present15 source years
  • Trials 19 17 with phase · 19 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 11 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2013 selected source window

IGF-1 LR3

1 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2026 selected source window

Insulin glargine-aldy

6 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 1 dated AP submissions · 2 official documents
  • DailyMed 5 exact SPL version receipts

Missing selected lanes: Clinical trials, Literature metadata, Safety.

Open the full map →

2012–2026 selected source window

Ipamorelin

17 dated records3/4 lanes present7 source years
  • Trials 2 0 with phase · 0 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 14 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

Kisspeptin-10

14 dated records2/4 lanes present7 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 13 13 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2003–2026 selected source window

KPV

13 dated records2/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 11 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2007–2026 selected source window

Lanreotide

74 dated records4/4 lanes present15 source years
  • Trials 13 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 49 25 with bibliography
  • Drugs@FDA 4 exact reviewed application connections
  • FDA history 24 dated AP submissions · 39 official documents
  • DailyMed 3 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2017–2026 selected source window

Larazotide

13 dated records2/4 lanes present5 source years
  • Trials 8 8 with phase · 8 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 5 5 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

1985–2026 selected source window

Leuprolide

232 dated records4/4 lanes present32 source years
  • Trials 117 51 with phase · 52 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 48 24 with bibliography
  • Drugs@FDA 25 exact reviewed application connections
  • FDA history 424 dated AP submissions · 450 official documents
  • DailyMed 17 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2012–2026 selected source window

Linaclotide

102 dated records4/4 lanes present15 source years
  • Trials 15 5 with phase · 5 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 49 25 with bibliography
  • Drugs@FDA 4 exact reviewed application connections
  • FDA history 25 dated AP submissions · 34 official documents
  • DailyMed 29 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2009–2026 selected source window

Liraglutide

173 dated records4/4 lanes present17 source years
  • Trials 82 18 with phase · 19 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 58 29 with bibliography
  • Drugs@FDA 13 exact reviewed application connections
  • FDA history 61 dated AP submissions · 94 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2015–2026 selected source window

Lixisenatide

64 dated records3/4 lanes present12 source years
  • Trials 6 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 34 14 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 7 dated AP submissions · 16 official documents
  • DailyMed 20 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2020–2026 selected source window

LL-37

31 dated records2/4 lanes present7 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2018–2026 selected source window

Lutetium Lu 177 dotatate

41 dated records3/4 lanes present6 source years
  • Trials 27 27 with phase · 27 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 10 10 with bibliography
  • Drugs@FDA 3 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Maridebart cafraglutide

23 dated records2/4 lanes present2 source years
  • Trials 19 13 with phase · 13 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2024–2026 selected source window

Mazdutide

22 dated records2/4 lanes present3 source years
  • Trials 17 13 with phase · 13 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 5 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

1997–2026 selected source window

Mecasermin

32 dated records3/4 lanes present18 source years
  • Trials 9 8 with phase · 9 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 18 18 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2006–2026 selected source window

Melanotan II

17 dated records2/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 16 16 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2013–2026 selected source window

Metreleptin

43 dated records3/4 lanes present14 source years
  • Trials 25 24 with phase · 25 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 15 15 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

MK-677

6 dated records2/4 lanes present4 source years
  • Trials 2 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 4 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2022–2026 selected source window

Motixafortide

17 dated records3/4 lanes present5 source years
  • Trials 7 7 with phase · 7 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 9 9 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2020–2026 selected source window

MOTS-c

43 dated records2/4 lanes present6 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 41 17 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

1990–2026 selected source window

Nafarelin

28 dated records3/4 lanes present9 source years
  • Trials 2 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1998–2026 selected source window

Nesiritide

56 dated records3/4 lanes present18 source years
  • Trials 25 25 with phase · 25 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1988–2026 selected source window

Octreotide

166 dated records4/4 lanes present25 source years
  • Trials 57 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 64 37 with bibliography
  • Drugs@FDA 27 exact reviewed application connections
  • FDA history 180 dated AP submissions · 72 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2025–2026 selected source window

Orforglipron

33 dated records3/4 lanes present2 source years
  • Trials 25 25 with phase · 25 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 7 7 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1980–2026 selected source window

Oxytocin

82 dated records3/4 lanes present24 source years
  • Trials 27 27 with phase · 27 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 8 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2024–2026 selected source window

Palopegteriparatide

16 dated records3/4 lanes present3 source years
  • Trials 4 2 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 9 9 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2012–2026 selected source window

Pasireotide

63 dated records3/4 lanes present15 source years
  • Trials 30 29 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2008–2026 selected source window

PEG-MGF

20 dated records1/4 lanes present14 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 20 20 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2020–2026 selected source window

Pegcetacoplan

51 dated records3/4 lanes present7 source years
  • Trials 23 21 with phase · 23 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2011–2026 selected source window

Peginesatide

34 dated records3/4 lanes present10 source years
  • Trials 14 14 with phase · 14 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 16 16 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Pemvidutide

6 dated records1/4 lanes present2 source years
  • Trials 6 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2026 selected source window

Petrelintide

12 dated records2/4 lanes present1 source years
  • Trials 10 8 with phase · 8 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 2 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2017–2026 selected source window

Plecanatide

46 dated records3/4 lanes present10 source years
  • Trials 12 4 with phase · 4 with status
  • Trial-publication graph 2 exact source-declared NCT ↔ PMID links
  • PubMed 16 2 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 15 official documents
  • DailyMed 14 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2001–2026 selected source window

Pramlintide

67 dated records3/4 lanes present15 source years
  • Trials 5 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 48 24 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 11 dated AP submissions · 20 official documents
  • DailyMed 11 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2024–2026 selected source window

Retatrutide

27 dated records3/4 lanes present3 source years
  • Trials 9 8 with phase · 8 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 17 7 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2024–2026 selected source window

Rusfertide

11 dated records3/4 lanes present3 source years
  • Trials 5 5 with phase · 5 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 5 5 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2003–2026 selected source window

Secretin

40 dated records3/4 lanes present19 source years
  • Trials 12 10 with phase · 12 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2018–2026 selected source window

Selank

13 dated records1/4 lanes present4 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 13 13 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2017–2026 selected source window

Semaglutide

290 dated records4/4 lanes present10 source years
  • Trials 140 64 with phase · 70 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 108 52 with bibliography
  • Drugs@FDA 5 exact reviewed application connections
  • FDA history 50 dated AP submissions · 109 official documents
  • DailyMed 19 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2006–2026 selected source window

Semax

42 dated records2/4 lanes present11 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 40 16 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

1990–2021 selected source window

Sermorelin

6 dated records2/4 lanes present6 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 2 2 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2020–2026 selected source window

Setmelanotide

70 dated records3/4 lanes present7 source years
  • Trials 14 6 with phase · 6 with status
  • Trial-publication graph 6 exact source-declared NCT ↔ PMID links
  • PubMed 41 18 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 13 official documents
  • DailyMed 10 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2026 selected source window

SLU-PP-332

1 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2025–2026 selected source window

Survodutide

18 dated records2/4 lanes present2 source years
  • Trials 14 11 with phase · 11 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2018–2026 selected source window

TB-500

7 dated records3/4 lanes present3 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2012–2026 selected source window

Teduglutide

58 dated records3/4 lanes present12 source years
  • Trials 30 30 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 24 24 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1999–2026 selected source window

Teriparatide

157 dated records3/4 lanes present24 source years
  • Trials 73 9 with phase · 10 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 62 35 with bibliography
  • Drugs@FDA 7 exact reviewed application connections
  • FDA history 38 dated AP submissions · 57 official documents
  • DailyMed 9 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2006–2026 selected source window

Terlipressin

63 dated records3/4 lanes present15 source years
  • Trials 30 29 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2010–2026 selected source window

Tesamorelin

45 dated records3/4 lanes present14 source years
  • Trials 11 4 with phase · 4 with status
  • Trial-publication graph 4 exact source-declared NCT ↔ PMID links
  • PubMed 21 1 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 12 dated AP submissions · 19 official documents
  • DailyMed 9 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2008–2026 selected source window

Tesofensine

11 dated records2/4 lanes present8 source years
  • Trials 7 7 with phase · 7 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 4 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2005–2026 selected source window

Thymopentin

32 dated records2/4 lanes present9 source years
  • Trials 7 7 with phase · 7 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2008–2026 selected source window

Thymosin alpha-1

48 dated records2/4 lanes present15 source years
  • Trials 18 17 with phase · 18 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2010–2026 selected source window

Thymosin beta-4

32 dated records2/4 lanes present5 source years
  • Trials 7 7 with phase · 7 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 25 25 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2022–2026 selected source window

Tirzepatide

219 dated records4/4 lanes present5 source years
  • Trials 108 54 with phase · 60 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 75 33 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 24 dated AP submissions · 60 official documents
  • DailyMed 22 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2000–2026 selected source window

Triptorelin

67 dated records3/4 lanes present17 source years
  • Trials 30 27 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 4 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2020–2026 selected source window

Trofinetide

27 dated records3/4 lanes present5 source years
  • Trials 3 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 20 20 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1998–2026 selected source window

Vasopressin

83 dated records3/4 lanes present17 source years
  • Trials 30 30 with phase · 30 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 30 30 with bibliography
  • Drugs@FDA 14 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

VK2735

6 dated records1/4 lanes present2 source years
  • Trials 6 6 with phase · 6 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2021–2026 selected source window

Vosoritide

58 dated records3/4 lanes present6 source years
  • Trials 10 5 with phase · 5 with status
  • Trial-publication graph 2 exact source-declared NCT ↔ PMID links
  • PubMed 35 11 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 3 dated AP submissions · 8 official documents
  • DailyMed 7 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2004–2026 selected source window

Ziconotide

58 dated records3/4 lanes present13 source years
  • Trials 4 0 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 46 22 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 10 official documents
  • DailyMed 6 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2021–2026 selected source window

Zilucoplan

25 dated records3/4 lanes present6 source years
  • Trials 11 10 with phase · 11 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 11 11 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →